Diaminopropanol tetraacetic acid
- Generic Name
- Diaminopropanol tetraacetic acid
- Drug Type
- Small Molecule
- Chemical Formula
- C11H18N2O9
- CAS Number
- 3148-72-9
- Unique Ingredient Identifier
- 949B9ZMO7M
- Background
Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others.
Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study
Not yet recruiting
- Conditions
- Vertebral Artery Stenosis
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 520
- Registration Number
- NCT06683300
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Beijing, China
Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients
Not Applicable
Not yet recruiting
- Conditions
- Coronary Arterial Disease (CAD)Percutaneous Coronary Intervention (PCI)Intravascular UltrasoundDual Antiplatelet Therapy
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- University Medical Center Ho Chi Minh City (UMC)
- Target Recruit Count
- 3566
- Registration Number
- NCT06648720
- Locations
- 🇻🇳
University Medical Center of Ho Chi Minh City, Ho Chi Minh, Vietnam
OCT or Angiography Guided De-escalation of DAPT
Early Phase 1
Not yet recruiting
- Conditions
- Neointimal CoverageST Elevation Myocardial InfarctionDual Antiplatelet TherapyAntiplatelet De-escalationOptical Coherence Tomography
- Interventions
- Procedure: OCT-guided PCIProcedure: Conventional angiography-based PCI
- First Posted Date
- 2024-04-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06339021
- Locations
- 🇨🇳
Northern Hospital, Shenyang, Liaoning, China
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
Phase 4
Recruiting
- Conditions
- ACS - Acute Coronary SyndromeCYP2C19 Polymorphism
- Interventions
- Drug: CYP2C19 Genotype Guided DAPT
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 1200
- Registration Number
- NCT06283888
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
Not Applicable
Not yet recruiting
- Conditions
- Acute Coronary Syndrome
- Interventions
- Drug: OPT-CAD score guided DAPT de-escalation
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 3490
- Registration Number
- NCT06216821
- Locations
- 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
Phase 4
Recruiting
- Conditions
- STEMI - ST Elevation Myocardial Infarction
- Interventions
- Drug: NOAC+DAPT
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 374
- Registration Number
- NCT06013020
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy
Phase 3
Recruiting
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- iVascular S.L.U.
- Target Recruit Count
- 2312
- Registration Number
- NCT05952206
- Locations
- 🇧🇪
Olv Aalst, Aalst, Belgium
🇧🇪IMELDA, Bonheiden, Belgium
🇧🇪CHU Marie Curie, Charleroi, Belgium
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Phase 4
Recruiting
- Conditions
- AnticoagulationCoronary Endarterectomy
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 202
- Registration Number
- NCT05782270
- Locations
- 🇨🇳
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
Phase 4
Recruiting
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI)
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Kindai University
- Target Recruit Count
- 2258
- Registration Number
- NCT05709626
- Locations
- 🇯🇵
Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan
Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
Not Applicable
Not yet recruiting
- Conditions
- Left Main Coronary Artery Stenosis
- Interventions
- Device: LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).Drug: P2Y12 inhibitor-based SAPT after short DAPT
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- IGLESIAS Juan Fernando
- Target Recruit Count
- 828
- Registration Number
- NCT05650411
- Locations
- 🇨ðŸ‡
Zurich University Hospital, Zürich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath